Diapositiva 4 de 25
Notas:
El estudio de las heparinas indica que “the incremental cost-effectiveness of inpatient low-molecular-weight heparin treatment ($7820 per QALY gained).
El estudio tambien indica que “the treatment with low-molecular-weight heparin was cost saving when as few as 8% of patients were treated at home.”
